Exelixis (EXEL) Q3 2024 earnings summary

Executive summary

• Achieved record Q3 2024 financial and operational performance, with total revenues of $539.5 million, driven by strong cabozantinib franchise results, robust demand in RCC, and expanding zanzalintinib pipeline.

• CABOMETYX maintained #1 TKI position in U.S. RCC, with 42% TRx share and highest new patient starts.

• Zanzalintinib development expanded, with collaboration with Merck covering six pivotal trials and launches targeted from 2026; projected to be main revenue driver by 2033.

• Achieved favorable U.S. District Court ruling on cabozantinib patent litigation, securing exclusivity until at least January 2030.

• Strategic focus on GU and GI oncology leadership, disciplined R&D investment, and expanded early-stage pipeline.

Financial highlights

• Q3 2024 total revenues reached $539.5 million, up 14% year-over-year; cabozantinib franchise net product revenues were $478.1 million, up 12% year-over-year.

• GAAP net income was $118 million ($0.40 per diluted share); non-GAAP net income was $135.7 million ($0.47 per diluted share).

• Cash and marketable securities totaled $1.71 billion as of September 30, 2024.

• R&D expenses were $222.6 million, down from prior year; SG&A expenses fell to $111.8 million.

• Gross margin remained strong at 96% for Q3 2024.

Outlook and guidance

• Raised 2024 total revenue guidance to $2.15–$2.2 billion and net product revenue guidance to $1.775–$1.825 billion.

• R&D expenses expected at $925–$950 million; SG&A at $475–$500 million; effective tax rate 21–22%.

• Projected Cabo U.S. peak sales of nearly $3 billion by 2030, with Zanza expected to drive over $5 billion in U.S. sales by 2033.

• Anticipates one Zanza launch per year starting as early as 2026, pending clinical and regulatory success.

• Guidance excludes restructuring and impairment charges.